Want to see HK:2359 full AI Analyst Report?
2359 Stock Chart & Stats
HK$204.20
-HK$0.20(-0.13%)
At close: 4:00 PM EDT
HK$204.20
-HK$0.20(-0.13%)
Day’s Range― - ―
52-Week RangeHK$96.70 - HK$219.20
Previous CloseN/A
Volume2.11M
Average Volume (3M)4.48M
Market Cap
HK$513.64B
Enterprise ValueHK$269.81B
Total Cash (Recent Filing)HK$46.63B
Total Debt (Recent Filing)HK$15.11B
Price to Earnings (P/E)19.1
Beta1.13
Next Earnings
Oct 26, 2026EPS Estimate
3.43Next Dividend Ex-DateN/A
Dividend Yield1.29%
Share Statistics
EPS (TTM)7.52
Shares Outstanding561,623,840
10 Day Avg. Volume6,239,488
30 Day Avg. Volume4,481,651
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)3.18
Price to Sales (P/S)5.57
P/FCF Ratio21.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$216.48Price Target Upside6.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)8.93
Revenue Forecast (FY)HK$70.05B
Bulls Say, Bears Say
Bulls Say
Integrated CRDMO PlatformAn integrated service platform can support customers across multiple stages of the drug-development lifecycle, encouraging repeat business as candidates advance. This breadth also creates opportunities to expand existing relationships across services and supports a durable position in outsourced pharmaceutical R&D.
Exceptional ProfitabilityVery high gross and net margins show that the company converts a substantial portion of revenue into earnings, providing resources for continued investment and resilience. If these economics persist, they can support competitive capabilities and strengthen earnings power over the next several quarters.
Low Leverage And Strong ReturnsConservative leverage limits balance-sheet pressure and preserves financial flexibility for operations, investment, or customer-driven capacity needs. Strong return on equity further indicates efficient use of the company’s capital base, supporting durable shareholder value creation if profitability remains robust.
Bears Say
Growth VolatilityThe 2024 revenue decline shows that demand and project activity can fluctuate across periods, making growth less predictable than the latest rebound suggests. Such volatility can complicate capacity planning and create uncertainty around the pace at which earnings and operating scale will compound.
Moderate Cash ConversionCash generation is improving, but operating and free cash flow remain below reported net income in the latest period. Persistent conversion below earnings could reduce internally available funding and make reported profitability less representative of cash that can support investment or shareholder returns.
Rising Absolute DebtAlthough leverage remains modest, higher absolute debt introduces a direction of travel that warrants monitoring. If borrowing continues to rise while profitability moderates, interest obligations and repayment needs could reduce financial flexibility and weaken the balance-sheet advantage over time.
WuXi AppTec Co., Ltd. Class H News
2359 FAQ
What was WuXi AppTec Co., Ltd. Class H’s price range in the past 12 months?
WuXi AppTec Co., Ltd. Class H lowest stock price was HK$96.70 and its highest was HK$219.20 in the past 12 months.
What is WuXi AppTec Co., Ltd. Class H’s market cap?
WuXi AppTec Co., Ltd. Class H’s market cap is HK$513.64B.
When is WuXi AppTec Co., Ltd. Class H’s upcoming earnings report date?
WuXi AppTec Co., Ltd. Class H’s upcoming earnings report date is Oct 26, 2026 which is today.
How were WuXi AppTec Co., Ltd. Class H’s earnings last quarter?
WuXi AppTec Co., Ltd. Class H released its earnings results on Aug 03, 2026. The company reported HK$2.532 earnings per share for the quarter, beating the consensus estimate of HK$1.82 by HK$0.712.
Is WuXi AppTec Co., Ltd. Class H overvalued?
According to Wall Street analysts WuXi AppTec Co., Ltd. Class H’s price is currently Undervalued.
Does WuXi AppTec Co., Ltd. Class H pay dividends?
WuXi AppTec Co., Ltd. Class H pays a Semiannually dividend of HK$0.589 which represents an annual dividend yield of 1.29%. See more information on WuXi AppTec Co., Ltd. Class H dividends here
What is WuXi AppTec Co., Ltd. Class H’s EPS estimate?
WuXi AppTec Co., Ltd. Class H’s EPS estimate is 3.43.
How many shares outstanding does WuXi AppTec Co., Ltd. Class H have?
WuXi AppTec Co., Ltd. Class H has 561,623,840 shares outstanding.
What happened to WuXi AppTec Co., Ltd. Class H’s price movement after its last earnings report?
WuXi AppTec Co., Ltd. Class H reported an EPS of HK$2.532 in its last earnings report, beating expectations of HK$1.82. Following the earnings report the stock price went up 1.369%.
Which hedge fund is a major shareholder of WuXi AppTec Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2359
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
WuXi AppTec Co., Ltd. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$216.48 (6.01% Upside)
HK$216.48 (6.01% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
77.79%
12-Months-Change
Fundamentals
Return on Equity
27.24%
Trailing 12-Months
Asset Growth
46.32%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
WuXi AppTec Co., Ltd. Class H
WuXi AppTec Co., Ltd. operates as an investment holding enterprise, delivering extensive research, development, and manufacturing services. These services primarily aid in the discovery, advancement, and production of small molecule pharmaceuticals, as well as sophisticated cell and gene therapies. The company maintains a global footprint, serving clients across the People's Republic of China, other Asian territories, the United States, Europe, and various international markets. Its operations are structured across six key segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. The firm's comprehensive offerings encompass contract research, development, and manufacturing organization (CRDMO) services, supporting new drug development from initial discovery phases all the way to commercial launch. This scope extends to diverse synthetic molecular types, including small molecules, oligonucleotides, peptides, and complex conjugates. Furthermore, WuXi AppTec provides biology services and solutions that facilitate projects from target identification to candidate selection and subsequent clinical progression. The company also offers integrated drug and medical device testing services, covering everything from preclinical assessments to clinical trials. An end-to-end solution is available to expedite the market entry of cell and gene therapies, alongside specialized drug discovery services for pharmaceutical and biotechnology clients, and full-spectrum clinical research support. WuXi AppTec Co., Ltd. was established in 2000 and its headquarters are located in Shanghai, People's Republic of China.
2359 Stock 12 Month Forecast
Average Price Target
HK$216.48
▲(6.01% Upside)
Technical Analysis
Genscript Biotech
―
Wuxi Biologics (Cayman)
―
Hangzhou Tigermed Consulting Co., Ltd. Class H
―
Pharmaron Beijing Co., Ltd. Class H
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―